CSL Seeks Disruption Of HAE Space With Monthly Prevention Product

 
• By Joseph Haas

Based on top-line Phase III data for garadacimab, CSL is preparing to submit the Factor XIIa inhibitor for US FDA approval for monthly prophylaxis of hereditary angioedema and expand the firm’s HAE franchise.

CSL heaquarters
CSL is planning to add a third HAE product to its portfolio • Source: Shutterstock

More from Strategy

More from Business